AN2 Therapeutics, Inc. — Q1 2024 Form 10-Q
Business context and period. Clinical-stage biopharmaceutical company developing treatments for serious infectious diseases. This unaudited report covers the three months ended March 31, 2024, compared with Q1 2023. AN2 has no approved products and generated no product revenue.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $14.7 million | $12.0 million |
| General and administrative expense | $3.6 million | $4.1 million |
| Total operating expenses | $18.3 million | $16.0 million |
| Other income, net | $1.7 million | $0.7 million |
| Net loss | $16.6 million | $15.3 million |
| Net loss per share, basic and diluted | $0.56 | $0.79 |
| Net cash used in operating activities | $17.6 million | $11.6 million |
| Cash, cash equivalents and investments | $118.1 million at March 31, 2024 | $138.8 million at December 31, 2023 |
Research and development spending rose 22%, primarily due to increased Phase 2/3 trial costs, personnel and outside services, partly offset by lower manufacturing and research-study costs. General and administrative expense declined 10%, largely reflecting lower prior-year IPO-related professional costs and insurance. Higher interest rates and investment balances increased other income. The lower per-share loss reflects a higher weighted-average share count, not a reduction in the net loss.
Q1 operating cash outflow increased by $6.0 million year over year. Investing activities provided $26.3 million, mainly from investment maturities; financing activities provided $0.3 million. Cash and investments totaled $118.1 million, including $24.7 million of cash and cash equivalents and $93.4 million of investments. Total liabilities were $10.7 million; the filing reports no debt balance. Current assets were $116.3 million and current liabilities $10.7 million. Profit margins are not meaningful given the absence of revenue.
Material developments, outlook and risks
- In February 2024, AN2 paused new enrollment in the Phase 3 portion of its Phase 2/3 trial of epetraborole for treatment-refractory MAC lung disease after blinded aggregate Phase 2 data suggested potentially lower-than-anticipated efficacy. Existing participants continued dosing. Phase 2 topline data were expected in August 2024; resumption and completion of Phase 3 enrollment are uncertain.
- Management reported a blinded review indicating a highly refractory study population, including patients with resistant background regimens and cavitary disease. The filing does not provide unblinded efficacy results.
- Management believes available cash and investments will fund the current operating plan for at least 12 months from the filing’s issuance. AN2 expects continued losses and states it will need substantial additional funding; financing may be unavailable or dilutive.
- Manufacturing progress: registration-batch API manufacturing was completed in Q3 2023, drug-product registration batches in Q1 2024, and the Phase 1 thorough QT study was completed.
- After quarter-end, in May 2024, NIAID exercised an additional contract option, increasing committed funding from $5.0 million to $8.8 million and extending the estimated contract completion to August 2026. The award allows up to $17.8 million overall, subject to options and qualifying work.
- Key risks include clinical efficacy, safety and enrollment uncertainty; reliance on single-source third-party research and manufacturing providers; additional capital needs; and the possibility that regulatory authorities require further trials. The filing also discloses material weaknesses in financial-reporting controls that remained unremediated as of March 31, 2024, although management states the financial statements were prepared in accordance with U.S. GAAP.
- No material legal proceedings were reported. No formal financial or clinical guidance beyond the stated trial timing and cash-runway assessment is provided.
Important facts for investors to verify
- August 2024 Phase 2 topline results and the company’s plans for the paused Phase 3 enrollment, including any FDA feedback or protocol changes.
- Whether the $118.1 million cash-and-investment balance and stated runway remain sufficient as trial costs and operating plans evolve.
- Execution and timing of the NIAID-funded work, including option conditions and eligible-cost reimbursements.
- Progress in remediating the disclosed internal-control material weaknesses and any effect on reporting reliability.
- Future financing needs and potential dilution; common shares outstanding were 29.8 million at March 31, 2024, with 5.3 million potentially dilutive securities excluded from diluted loss per share.